the adverse cardiovascular effects of RSG in diabetic patients without CKD, and the data in patients with CKD remain conflicting. This study examines the effect of RSG on vascular function in patients with CKD. Methods. A randomized, double-blind placebo-controlled study comparing RSG 4 mg daily (n ¼ 35) with placebo (n ¼ 35) for 8 weeks was performed in CKD subjects. Primary outcome measures were flow-mediated dilatation (FMD), systemic arterial compliance (SAC) and augmentation index (AIx). Secondary outcomes included glyceryl trinitrate-mediated dilatation (GTN-MD), pulse-wave velocity (PWV), lipids, blood pressure, homoeostasis model assessment (HOMA), adiponectin, high-sensitivity C-reactive protein (hs-CRP) and high-sensitivity interleukin 6 (hs- 
Introduction
The increased risk of cardiovascular disease (CVD) in subjects on dialysis and in those with milder degrees of renal impairment may relate to the presence of traditional, novel and renal-specific cardiovascular risk factors, such as insulin resistance (IR), inflammation and dyslipidaemia. However, the relative contribution and significance of these cardiovascular risk factors in predicting cardiovascular outcomes in chronic kidney disease (CKD) is largely unknown and continues to be debated [1] .
Measures of vascular function, which include endothelial function, arterial compliance and arterial stiffness, have been validated as estimates of cardiovascular risk in subjects with and without CKD. Endothelial dysfunction (ED) is an early phase of atherosclerosis associated with an abnormality in the physiology of nitric oxide (NO) [2] . ED can be assessed by measuring in vivo plasma markers such as von Willebrand factor (vWF) and non-invasively using high-resolution ultrasonography to measure post-ischaemic flow-mediated dilatation (FMD) and glyceryl trinitrate-mediated dilatation (GTN-MD) of the peripheral conduit arteries. ED is prevalent in subjects with CKD and is predictive of future cardiac events in non-renal patients [3] . Systemic arterial compliance (SAC), as measured by pulse contour analysis of the radial artery, gives an estimate of large conduit artery (C1) and small microcirculatory artery (C2) compliance. Small artery compliance (C2) is a known risk marker for cardiovascular events in non-renal subjects [4] . Arterial stiffness, as measured by augmentation index (AIx) and pulse-wave velocity (PWV) using applanation tonometry, is increased in CKD and has been shown to predict all-cause and cardiovascular mortality in patients on haemodialysis [5] .
IR is an independent predictor of cardiovascular risk in subjects with CKD and is associated with hypertension, dyslipidaemia, inflammation, increased oxidative stress, decreased adipocytokines and fibrinolysis, all of which may impact on vascular function [6] . IR is present in early CKD and shown to be an independent predictor of ED in Stages 3-5 CKD patients [3] .
Thiazolidinediones (TZDs), a class of oral antidiabetic agent, act as ligands of the peroxisome proliferatoractivated receptor-c (PPAR-c) to lower IR and improve glycaemic control. Their beneficial effects on adipocyte differentiation with increase in adiponectin levels, lipid metabolism, inflammation, coagulation and vascular function suggest potential effects on lowering cardiovascular risk [7] . While TZDs have been shown to improve ED in diabetic and non-diabetic subjects, there are growing concerns regarding the cardiovascular safety of TZDs in non-renal subjects, particularly rosiglitazone (RSG) [8] . Recently, international drug regulatory bodies have imposed further restrictions on the use of RSG in North America and the drug has been suspended from the European market unless further data showing benefit can be presented [9, 10] . While similar concerns have been raised regarding thiazolidinedione use in dialysis patients, overall, the cardiovascular safety data with thiazolidinedione use in CKD subjects remains conflicting [11] [12] [13] .
At the inception of this study, which pre-dated data linking RSG use with increased CVD risk, uncontrolled trials of short-term RSG therapy had been shown to safely lower IR in patients on renal replacement therapy and improve ED in renal transplant recipients [14] [15] [16] . No studies had assessed the effect of TZDs on vascular function or cardiovascular outcome in pre-dialysis CKD subjects. Thus, we hypothesized that insulin-sensitizing agents, such as RSG, may lower risk for CVD in patients with CKD and aimed to assess the effects of RSG on endothelial function, SAC and arterial stiffness in CKD. We also examined the effect of RSG on IR, inflammation, adipocytokines and lipid and lipoprotein profiles to elucidate potential mechanisms. Non-diabetic and non-insulin-requiring type 2 diabetic CKD patients, current smokers as well as those on antiplatelet and antihypertensive agents were included. Exclusion criteria were as follows: Type 1 diabetes mellitus, nephrotic-range proteinuria, liver enzymes greater than two times upper limit of normal, alcohol consumption greater than three standard drinks/day, cardiovascular event or unstable CVD in preceding 6 months, symptomatic or New York Heart Association Stage III or IV heart failure, haemoglobin <110 g/L, significant psychiatric disorder, active infection or inflammation, pregnancy or planning a pregnancy. Following the publication of a meta-analysis raising concern regarding the cardiovascular safety of RSG, the study protocol was modified to recruit only non-diabetic CKD subjects without prior history of CVD (n ¼ 19) [17] .
Research design and methods
We conducted a randomized, double-blind parallel-group study examining the effects of RSG at 4 mg/day or matching placebo on vascular function in patients with Stages 3-4 CKD for a period of 8 weeks. Block randomization was performed by a central pharmacy using random number tables and substratified for diabetes status. All participants continued on their regular medications. Study participants and research staff were blinded to treatment allocation.
Clinical, laboratory and vascular function tests were performed at baseline and after 8 weeks of study medication. The primary outcome measures were endothelial function as assessed by post-ischaemic FMD of the brachial artery, SAC as assessed by small artery compliance (C1) and large artery compliance (C2) and arterial stiffness as assessed by AIx. Secondary outcome measures were PWV, IR as measured by the homoeostasis model assessment (HOMA) score, lipid and lipoprotein profile [cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein B and A-I], adipocytokine (adiponectin), in vivo markers of inflammation high-sensitivity C-reactive protein [high-sensitivity C-reactive protein (hs-CRP), high-sensitivity interleukin 6 (hs-IL-6)] and endothelial function (vWF) and 24 h ambulatory blood pressure monitoring (ABPM).
Safety of study medication was assessed after 4 weeks of therapy by self-reporting of symptoms, clinical review (weight measurement, chest examination and assessment of oedema) and laboratory measures of haemoglobin, blood glucose and liver enzymes. Pill counting was used to assess compliance.
This study was approved by the Ethics Committees of Royal Perth Hospital and Sir Charles Gairdner Hospital. Written informed consent was obtained from all participants and the study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12605000690651).
Clinical and laboratory methods
Variables were measured using standard laboratory techniques unless stated otherwise. Serum lipids, apolipoproteins, glucose, insulin, hs-CRP and hs-IL-6 were determined by methods described previously [3] . IR was calculated using the HOMA score [fasting insulin (IU/mL) 3 serum glucose (mmol/L)/22.5], where a higher HOMA score reflects greater degree of IR. Adiponectin was measured using enzyme immunoassay kits (Quantikine; R&D Systems, Minneapolis, MN). vWF antigen was assessed using an immunoturbidimetric technique using a STALiatestÒvWF kit (Diagnostica STAGO, Parsippany, NJ) and Diagnostica Stago STAR-automated coagulation analyser. The interassay coefficient of variation of all analytical assays was <7%, except for hs-IL-6, which was 9.9-16.5%.
Vascular function tests
Endothelial function. Brachial artery ultrasonography (Acuson Aspen 128 ultrasound device; Acuson Corporation, Mountainview, CA) was carried out to determine endothelium-dependent post-ischaemic FMD and endothelium-independent GTN-MD [3] . Maximal FMD and GTN-MD responses were calculated as percentage of change in brachial artery diameter from baseline.
Arterial compliance. SAC was measured using a HDI-Pulse-Wave CR2000 Research Cardiovascular Profiling System (Hypertension Diagnostics Inc., Eagan, MN). Radial pulse-contour analysis was used to derive C1 and C2 using a modified version of the Windkessel model.
Arterial stiffness. The SphygmoCorä pulse-wave analysis system (AtCor Medical, Pty Ltd, West Ryde, NSW, Australia) was used to determine arterial stiffness, namely AIx and carotid-femoral PWV. This system employs an applanation tonometer to measure radial artery pressure waveforms and electrocardiogram-gated carotid and femoral arterial waveforms. Previously validated generalized transfer functions are then used to obtain AIx and PWV. For AIx, at least two consecutive radial pulse wave readings, with quality index >80%, were recorded and data were taken as the mean of the best recordings. In our hands, the intraobserver error for AIx in a sample of 10 healthy volunteers was~20%. To minimize interobserver variation, the same trained observer performed the baseline and post-treatment recordings.
Ambulatory blood pressure monitoring.
ABPM and heart rate were recorded for 24 h using the SpaceLabs monitor (Model 90217; SpaceLabs Medical Inc., Washington, WA) at baseline and after 8 weeks of therapy. Data were recorded at 20-min intervals during awake hours (day) and 30-min intervals during sleep (night).
Statistical methods and analysis
Statistical analyses were performed using SPSS, version 17.0 (Statistical Package for Social Sciences; SPSP Inc., Chicago, IL). Data are presented as mean AE SD and skewed variables as geometric mean and 95% confidence interval. Skewed variables were log transformed prior to statistical analysis. Baseline treatment group comparisons were performed using the independent t-test, while general linear modelling adjusting for baseline variables was used to compare treatment groups after 8 weeks of therapy. Categorical variables were compared using chi-square (v 2 ) and Fisher exact tests. Statistical associations were examined using simple, stepwise and multiple linear regression methods. A longitudinal random effects regression using Intercooled Stata 10.1 (StataCorp, www.stata.com) was used to analyse the ABPM readings. Statistical significance is defined at the 5% level.
The study was powered to detect differences in the primary outcome measures only. With an a error of 0.05 and 80% power, a minimum of 29 patients per group was required to detect a minimum absolute 2% difference in FMD while allowing for a within-group SD of 2.3 [18] . We studied 35 patients per group to allow for possible increased variance post-treatment. We replaced a patient who dropped out with a new case to maintain the sample size. Regarding arterial compliance, we were adequately powered to detect a minimum difference in elasticity index of at least 2.5 allowing for a within-group SD of 2.7-3.0 in our hands and a 20% change in AIx, which potentially reflect a 2-to 3-fold change in risk for CVD morbidity and mortality based on previous studies [5] . Figure 1 shows the flow of patients from recruitment through randomization and end of study. Of the 83 patients screened, 71 eligible patients were randomized to receive either RSG 4 mg daily (n ¼ 36) or matching placebo one tablet daily (n ¼ 35) for 8 weeks. The one patient who withdrew from the RSG arm due to nausea and light-headedness was replaced, and 70 patients completed the study. Baseline clinical characteristics were not significantly different between the treatment groups ( Table 1) . Causes of renal disease were not significantly different between groups (v 2 P ¼ 0.78) and included chronic glomerulonephritis (n ¼ 13), diabetic nephropathy (n ¼ 8), hypertensive nephrosclerosis (n ¼ 10) and others (n ¼ 39). There were eight patients in each group (23%) with noninsulin-requiring type 2 diabetes. A prior history of CVD was present in 14.3% (n ¼ 5) of patients on placebo and 11.4% (n ¼ 4) of patients on RSG (v 2 P ¼ 0.72). There were a small number of smokers in both treatment arms [RSG 8.6% (n ¼ 3) versus placebo 5.7% (n ¼ 2), v 2 P ¼ 0.83]. Most patients were receiving antihypertensive agents, particularly blockers of the renin-angiotensin-aldosterone system (RAAS) (RSG 94.2% versus placebo 91.4%, v 2 P ¼ 0.64) and statins (RSG 68.6% versus placebo 65.7%, v 2 P ¼ 0.80). Antihypertensive medication use was not different between groups at baseline, except for diuretic therapy, which was more frequent in the RSG group (RSG 66.7% versus placebo 33.3%, v 2 P ¼ 0.03). As shown in Table 1 , eGFR, haemoglobin, serum albumin and level of proteinuria were not significantly different between groups. Similarly, markers of IR (glucose, insulin, HOMA score), lipid and lipoprotein parameters, in vivo markers of inflammation and endothelial function and adiponectin were not significantly different between groups at baseline. Finally, groups were not significantly different at baseline for all measures of vascular function and ABPM readings ( Table 2) . Table 3 lists the effects of RSG compared with placebo at 8 weeks on IR, adiponectin, lipids, lipoproteins and apolipoproteins and inflammatory markers. Compared with placebo, short-term RSG therapy significantly lowered serum insulin concentration (P ¼ 0.04) and HOMA score (P ¼ 0.04) without significantly changing fasting blood glucose and HbA1 C concentration. RSG also significantly increased adiponectin concentration (P < 0.0001). RSG therapy lowered hs-CRP (P ¼ 0.04) and per cent vWF activity (P ¼ 0.01) but not hs-IL-6 concentration. RSG was also associated with a significant increase in plasma triglyceride concentration (P ¼ 0.01) with no significant effect on total cholesterol, LDL-C, HDL-C, apolipoprotein A-I and apolipoprotein B concentrations. RSG did not significantly alter urine protein:-creatinine ratio. Table 4 lists the effects of RSG compared with placebo at 8 weeks on measures of vascular function and 24-h ABPM readings. Compared with placebo, RSG was not associated with a significant change in any of the measures of vascular function. Furthermore, RSG therapy did not significantly affect 24-h mean systolic and diastolic blood pressures and heart rate.
Results

Safety and tolerability
Compliance with study medications was high and not significantly different between the groups (RSG 95.3% and placebo 95.4%, v 2 P ¼ 0.95). Of the 70 subjects who completed the study, 49% (17/35) of subjects receiving RSG and 37% (13/35) of patients on placebo reported adverse events (v 2 P ¼ 0.33). One patient randomized to RSG withdrew 1 week after commencing study medications due to side effects (nausea and light-headedness). Compared with placebo, more subjects on RSG reported gastrointestinal (RSG n ¼ 8 versus placebo n ¼ 1) and flu-like symptoms (RSG n ¼ 4 versus placebo n ¼ 2). One subject on RSG reported worsening peripheral oedema, while another developed mild pancytopaenia that resolved spontaneously following cessation of study medications. RSG significantly lowered haematocrit [RSG 0.37 AE 0.05; placebo 0.39 AE 0.05, P ¼ 0.004] but had no significant effect on erythropoietin or diuretic use. RSG had no significant effect on liver transaminases or renal function. Compared with placebo, there was no change in body weight, episodes of heart failure, angina or myocardial infarction in the RSG group.
Discussion
This study demonstrates that while short-term RSG therapy significantly lowered IR, hs-CRP, vWF and increased adiponectin levels, it had no effect on vascular function in the subjects with mild to moderate CKD and was associated with an increase in serum triglyceride levels. Short-term use of RSG was associated with more gastrointestinal side effects but not cardiovascular events.
In patients with CKD, observational studies have reported conflicting findings on the effect of TZDs on cardiovascular outcomes. While TZDs were shown to improve Fig. 1 . Recruitment and patient randomization major cardiovascular end points in diabetic patients with CKD and insulin-free type 2 diabetic subjects on haemodialysis, RSG was associated with increased risk for allcause and cardiovascular mortality in haemodialysis patients [11] [12] [13] . The suggested mechanism by which RSG may improve cardiovascular risk includes improvement in vascular function by positive effects on IR, adipocytokines and inflammation [7] . The only study reporting a beneficial effect of TZDs on vascular function in CKD subjects was an observational uncontrolled study using RSG in 10 renal transplant recipients [15] . In contrast, our placebo-controlled study using RSG demonstrated that despite an improvement in IR, adiponectin and hs-CRP, vascular function and hs-IL-6 failed to improve, and triglycerides worsened. RSG has been shown previously to worsen plasma triglycerides, which may contribute to the lack of benefit on vascular function observed in this study [19] .
Furthermore, although RSG significantly lowered serum levels of the proinflammatory marker hs-CRP, it had no effect on hs-IL-6. Inflammation plays a central role in the pathogenesis of impaired vascular function and atherosclerosis. While TZDs have been shown to reduce markers of inflammation primarily by the PPAR-a rather than PPAR-c receptor, they also have proinflammatory properties that are independent of PPAR-c activation [7, 20, 21] . Given that RSG is a highly selective PPAR-c agonist, the absence of PPAR-a activation may result in an overall proinflammatory effect that may contribute to the lack of positive effect of RSG on vascular function.
As expected, we found that RSG was associated with a significant increase in adiponectin levels, which has known antiatherogenic and anti-inflammatory properties, and is thus potentially cardioprotective. Increased adiponectin levels have been associated with improvement in endothelial function, suggesting that thiazolidinedioneinduced increase in adiponectin may improve vascular function [22] . However, while low adiponectin levels have been strongly associated with increased risk of cardiovascular events in several observational studies of patients on renal replacement therapy, the opposite association has also been reported in pre-dialysis CKD subjects [23] . This conflicting data may be explained by the altered metabolism of adiponectin and its isoforms in the setting of CKD negating its beneficial effects on the vasculature [23] . Although we did not detect a change in weight and blood pressure to indicate fluid retention, subclinical fluid retention remains a possibility in this population with altered fluid homoeostasis. Increased intravascular volume may contribute to increase myocardial oxygen demand and altered vessel wall function, potentially abrogating any beneficial effects of TZDs on the vascular wall in CKD. Thus, the co-occurrence of beneficial and adverse effects of RSG on cardiovascular risk factors may explain the observed dissociation between lowering of IR and lack of effect on vascular function with RSG therapy in this study.
Finally, the study participants were principally well, ambulant Stages 3-4 CKD subjects, the majority of which were non-smokers, with a significant proportion of subjects on RAAS blockers and statin therapy. Furthermore, we did not select for CKD subjects with abnormal vascular function nor did we select for subjects with IR and only a small proportion of patients in each group had Type 2 diabetes. Thus, a beneficial effect of a single agent on vascular function in a population with adequately controlled risk factors Data presented as mean 6 SD and geometric mean (95% confidence interval). SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.
is less likely and may require longer periods of treatment before changes in vascular function are observed. Lastly, the lack of benefit of RSG therapy on vascular function in this study may relate to IR not being the singular driving force in determining cardiovascular risk in CKD. Specifically, accelerated arteriosclerosis with marked vascular (intimal and medial) calcification is a key determinant of arterial stiffness and cardiovascular mortality in CKD and strongly relates to disturbed calcium/phosphate metabolism and osteogenic differentiation of vascular smooth muscle cells [24] . Potential limitations of the study include the use of a submaximal dose of RSG and short duration of therapy. Although other studies have shown a rapid effect of TZDs on endothelial function, a larger dose (8 mg/day) and longer duration of treatment may have allowed for measurable structural changes to occur within the vessel wall in this study [15] . While this study does not demonstrate a beneficial effect of RSG on vascular function in CKD, the findings cannot be extended to other TZDs. The possibility of a cardioprotective effect of pioglitazone due to its more favourable effects on endothelial function, inflammatory markers and renal function is currently being evaluated in a 6-month randomized placebo-controlled trial of non-diabetic CKD patients with creatinine clearance of 60 mL/min by the Cockroft-Gault equation. This study also has change in arterial stiffness, oxidative stress, urea clearance, estimated eGFR by MDRD, microalbuminuria and number of cardiovascular events within 6 months as secondary end points (http://clinicaltrials.gov/ct2/show/ NCT00586261).
In conclusion, while short-term RSG therapy improved insulin sensitivity, hs-CRP and vWF, it worsened serum triglycerides and had no effect on hs-IL-6, non-invasive measures of vascular function and ABPM. The recent restrictions on RSG use in the USA and suspension of RSG in Europe are likely to limit further clinical cardiovascular end-point trials of RSG in CKD patients. As such, this study showing no effect of RSG on validated surrogate cardiovascular end points suggests a lack of cardiovascular benefit of RSG therapy in subjects with CKD.
